| Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 23235770 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment. |
| | |
Authors:
|
Khurum H Khan; Audrey Fenton; Eimer Murtagh; James Ja McAleer; Alison Clayton |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Tumori Volume: 98 ISSN: 2038-2529 ISO Abbreviation: Tumori Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-12-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0111356 Medline TA: Tumori Country: Italy |
Other Details:
|
Languages: eng Pagination: 139e-42e Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Collecting duct carcinoma presenting uncommon metastatic features.
Next Document: Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esop...